Thomas Bachmann Appointed President of Bruker BioSpin Group
News Aug 19, 2013
The Bruker BioSpin Group is the global market and technology leader in analytical and preclinical magnetic resonance instrumentation, with major operations in Germany,Switzerland, France and the United States, as well as numerous applications and customer service centers around the world. The Bruker BioSpin Group operates in two divisions:
• Magnetic Resonance Spectroscopy (MRS) division, consisting of the three business units nuclear magnetic resonance (NMR), electron paramagnetic resonance (EPR) and compact magnetic resonance (CMR)
• Preclinical Imaging (PCI) division, consisting of the preclinical imaging product lines magnetic resonance imaging (MRI), magnetic particle imaging (MPI), X-ray micro-CT, as well as optical and PET/SPECT/CT molecular imaging.
Frank Laukien, Bruker's President and Chief Executive Officer, stated: "I am very pleased to welcome Thomas Bachmann to Bruker. His life-science background and his broad management experience will allow him to lead our excellent BioSpin management team in order to further accelerate our innovation, profitable growth and operational excellence initiatives. Thomas will be a valuable addition for all of Bruker due to his diversified industrial experience, his global customer and operations exposure, and his successful track record."
"Bruker is a premier brand in our analytical, life-science and diagnostic instruments industry, and an exceptional company that I have come to know well over the past few years," saidThomas Bachmann. "I am delighted to join Bruker, and together with an experienced management team I look forward to further developing the Bruker BioSpin Group. With emphasis on innovation for customers, applications development and market expansion, paired with operational excellence and margin expansion, Bruker BioSpin has significant value creation potential over the years to come."
Thomas Bachmann brings over twenty-five years of global experience in sales and marketing, in leading and transforming complex businesses, as well as in strategy and business development to his new role as Bruker BioSpin Group President, including experience as a CEO of two publicly traded companies. From 2005 until 2012, Mr. Bachmann served as CEO of Tecan Group, where he increased operational effectiveness, expanded into new businesses, developed emerging markets, created a solid organization, established regulatory competence and compliance, grew profitability and built a strong balance sheet. From 2002 until 2004, he was CEO of the Arbonia-Forster Group's Steel Systems Business, a global provider of building supplies. From 1985 until 2002, Mr. Bachmann served in various roles as global Sales and Marketing Director, Business Unit Director and Senior Vice President of Corporate Development at Rieter Holding, a global provider of textile machinery and plants, as well as an automotive supplier of acoustic- and thermal insulation systems. Mr. Bachmann holds a B.Sc. in Mechanical Engineering and an Executive MBA from IMD Business School in Switzerland.
Researchers Reveal How Superbug Secretes It’s ToxinNews
Monash University’s Biomedicine Discovery Institute (BDI) researchers have created the first high-resolution structure depicting a crucial part of the ‘superbug’ Pseudomonas aeruginosa. The image identifies the ‘nanomachine’ used by the highly virulent bacteria to secrete toxins, pointing the way for drug design targeting this.READ MORE
New Drug Class: Potential Therapeutics for Alzheimer’s Disease?News
One step closer to an Alzheimer's treatment? Novel class of drugs more precisely blocks production of toxic forms of beta-amyloid.READ MORE
Survival Trait Evolution Shown in 54 Million-Year-Old Sea TurtleNews
High-resolution analytical techniques of pigment, beta-keratin and muscle proteins from a 54 million-year-old sea turtle hatchling revealed that a pigment-based survival trait common to modern sea turtles evolved at least 54 million years ago.READ MORE